Insmed Incorporated (INSM)

Over the past six months, Insmed's stock has increased significantly. Positive Phase III trial results for brensocatib, regulatory approvals including European Commission approval of Brinsupri, a proposed public offering of common stock, and strong third-quarter financial results contributed to this surge. Analyst upgrades and price target increases also followed these positive developments.

Information regarding specific demand seasonality for Insmed, Inc.'s products and services is not explicitly detailed in the provided search results. Demand for its therapies is likely driven more by disease prevalence, diagnosis rates, and treatment efficacy rather than typical seasonal consumer patterns.

Insmed, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, particularly pulmonary and inflammatory conditions. Their primary product is ARIKAYCE, used to treat refractory nontuberculous mycobacterial lung infections. The company's pipeline includes brensocatib, in Phase 3 trials for non-cystic fibrosis bronchiectasis and Phase 2 trials for other conditions, and treprostinil palmitil inhalation powder (TPIP), in Phase 3 trials for pulmonary hypertension associated with interstitial lung disease and Phase 2 trials for pulmonary arterial hypertension. Brensocatib recently received approval in the European Union for bronchiectasis.

Insmed is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, with offices and research locations throughout the United States, Europe, and Japan. They have corporate offices in France, Germany, Ireland, Italy, Japan, Netherlands, Switzerland, and the UK. Research sites are located in San Diego, CA; Lebanon, NH; Bridgewater, NJ; and Cambridge, UK.

Insmed has maintained a strong brand reputation in the biopharmaceutical industry over the past year. The company has been recognized as a top employer, ranking No. 1 on Science magazine's Top Biopharma Employers List for four consecutive years, and for the fifth year in a row in 2025. No significant negative events affecting Insmed's reputation were found in the past year.

Insmed Incorporated's ownership is primarily concentrated among institutional investors, who hold approximately 99.26% of the company's shares. Major institutional owners include JPMorgan Chase & Co, Darwin Global Management, Ltd., Vanguard Group Inc, BlackRock, Inc., Fmr Llc, Capital International Investors, Price T Rowe Associates Inc /md/, Baker Bros. Advisors Lp, and D. E. Shaw & Co., Inc. Individual investors, or insiders, own approximately 0.86% to 3% of the stock. Richard S. Kollender is the largest individual shareholder. Recent insider selling activity has been observed.